Protagonist Therapeutics (PTGX) Tops Q1 EPS by 207c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q1 EPS of $3.26, $2.07 better than the analyst estimate of $1.19. Revenue for the quarter came in at $254.95 million versus the consensus estimate of $120 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Lennar Corp. (LEN) Misses Q2 EPS by 1c
• Independent Bank receives regulatory approval for HCB Financial acquisition